Get started
Work

P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.annonc.2021.05.166
Authors: J. Tabernero, T. Bekaii-Saab, M. Safont Aguilera, A. Cubillo, R. Garcia-Carbonero, L. Limon, N. Rodríguez-Salas, C. Tournigand, C. Borg, K. Raghav, G. Finley, J. Strickler, F. Beier, S. Salim, R. Esser, E. Liu, S. Adrian, C. López-López
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Mayo Clinic Hospital, Universitat de València, Hospital Universitario HM Sanchinarro, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Hospital Universitario Virgen del Rocío, Hospital Universitario La Paz, Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Besançon, The University of Texas MD Anderson Cancer Center, Allegheny Health Network, Duke University, Duke Medical Center, Merck KGaA, Darmstadt (Germany), Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, FibroGen, Baxalta, Merck KGaA, Taiho Pharmaceutical, Exelixis, Les Laboratories Pierre Fabre, Halozyme, Agios Pharmaceuticals, BeiGene, Incyte, Cancer Research UK, University of Cambridge, University of Oxford, Cambridge University Hospitals, Dainippon Sumitomo Pharma, Eisai, Astellas Pharma, Servier, Yakult Honsha, Ono Pharmaceutical, Ipsen, Sirtex Medical, Chugai Pharmaceutical, Eli Lilly Japan, Daiichi Sankyo Europe
OpenAlex ID: W3201010822
Cites:
Cited by:
Related to: 10